Menisy

Betahistine, the active ingredient in Menisy, is a histamine analogue presented as an oral tablet for oral use. It is used to relieve vertigo and tinnitus associated with Ménière’s disease in adults.

GNH USA supplies Menisy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Menisy (betahistine) is used in vestibular disorders to manage symptoms related to inner‑ear dysfunction.

- Meniere's disease: reduces the frequency and severity of vertigo attacks and may lessen associated tinnitus. - Vertigo: helps alleviate episodes of dizziness caused by vestibular imbalance. - Tinnitus: may improve perception of ringing in the ears linked to inner‑ear disorders.

Betahistine is generally well tolerated, but some patients experience adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional upset stomach. - Gastric discomfort: dyspepsia or mild abdominal pain. - Dry mouth: transient reduction in salivation. - Drowsiness: occasional mild fatigue.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, or urticaria. - Anaphylaxis: rare but potentially life‑threatening hypersensitivity. - Severe hypotension: marked drop in blood pressure. - Cardiac arrhythmia: uncommon irregular heartbeat. - Hepatic dysfunction: rare liver enzyme elevation.

Before using Menisy, consider the following safety points.

- Pregnancy: consult a healthcare professional; safety data are limited. - Breastfeeding: use with caution; monitor infant for any adverse effects. - Elderly patients: monitor for hypotension and dizziness. - Concomitant antihistamines: may reduce therapeutic benefit. - Renal impairment: dose adjustment may be required. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Betahistine may interact with other medicines; review the following categories.

Major Interactions (Avoid): - H1‑blocking antihistamines: can diminish betahistine’s efficacy. - Monoamine oxidase inhibitors (MAOIs): may increase risk of hypertensive episodes.

Moderate Interactions (Monitor Closely): - CYP450 inhibitors (e.g., erythromycin): may raise plasma concentrations. - Diuretics: could enhance changes in inner‑ear fluid balance. - Antihypertensive agents: monitor blood pressure for additive lowering effects.